Effectiveness of platelet transfusion in acute leukemic pediatric patients: a prospective study

S. Subash, D. Umesh


Background: In India, leukemia account for 25-35% of hematologic malignancies affecting children. Pediatric patients with acute leukemia have to undergo chemotherapy, which may cause protracted thrombocytopenia due to the cytotoxic effects of the drugs prescribed and due to the primary disease. The aim of the present study was to evaluate the need for platelet transfusion in leukemic children and to assess the effectiveness of platelet transfusion among them.  

Methods: A prospective observational study was conducted in the Department of transfusion medicine and hematology at a tertiary care teaching hospital for a period of one year. The study population included children diagnosed as acute leukemia in the age group 1-12 years. The transfusion was given depending upon the clinical sign of bleeding and the platelet count. The pre and post transfusion platelet count (24 hours after the transfusion) were estimated using hematology analyzer. Statistical analysis was performed using SPSS software.  

Results: 198 episodes of platelet transfusion were given to 30 children with acute leukemia. It was found for 95% CI of the mean between the pre and post-transfusion platelet count for single, double units and more than two units platelet transfusion, the rise in platelet count was significant (p<0.0001) and there was no refractoriness. All children were negative for transfusion transmissible infections at the end of the study.

Conclusions: In the present study, the clinical management of children with acute leukemia has significantly improved with use of platelet transfusions and thereby, the mortality rate due to bleeding complications has dropped rapidly with remarkable clinical improvement in clinical outcomes.


Leukemia, Platelet transfusion, Refractoriness

Full Text:



Tyagi BB, Manoharan N, Raina V. Childhood Cancer Incidence in Delhi, 1996-2000. Indian J Med Paed Oncol.2006;27(4):13-8.

Swaminathan R, Rama R, Shantha V. Childhood cancers in Chennai. Int J Cancer. 2008;122(11):2607-11.

Bruce Cameron, Gail Rock, Bernard Olberg, and Doris Neurath. Evaluation of platelet transfusion triggers in a tertiary care hospital. Transfusion. 2007; 47(2):206-11.

Valeri CR, Khuri S, Ragno G. Nonsurgical bleeding diathesis in anemic thrombocytopenic patients: role of temperature, red blood cells, platelets, and plasma‐clotting proteins. Transfusion. 2007. 1;47(s4).

Cid J, Lozano M. Lower or higher doses for prophylactic platelet transfusions: results of a meta‐analysis of randomized controlled trials. Transfusion. 2007;47(3):464-70.

Jeffrey Mc Cullough. Current issues with platelet transfusion in patients with cancer. Semin Hematol, 2000:37(2);3-10.

Pisciotto PT, Benson K, Hume H, Glassman AB, Oberman H, Popovsky M et al. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or Oncology patients. Transfusion 1995,35(6):498-502.

Higby DJ, Cohen E, Holland JF, Sinks L. The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double-blind study. Transfusion. 1974;14(5):440-6.

Gmur J, Burger J, Schanz U, Fehr J, Schaffner A. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. The Lancet.1991;338(8777):1223-6

Schiffer CA, Dutcher JP, Aisner J, Hogge D, Wiernik PH, Reilly JP. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood. 1983 Oct 1;62(4):815-20.

Heddle NM. Controversy concerning platelet dose. ISBT science series. 2007;2(1):220-5.

Bishop JF, McGrath K, Wolf MM, Matthews JP, De Luise T, Holdsworth R et al. Clinical Factors Influencing the efficacy of pooled platelet Transfusions. Blood 1998;71(2);383-7.

Heim D, Passweg J, Gregor M, Buser A, Theocharides A, Arber C et al. Patient and product factors affecting platelet transfusion results. Transfusion. 2008;48(4):681-7

E. Patten Controversies in transfusion medicine. Prophylactic platelet transfusion revisited after 25 years. Transfusion.1992;32;4:381-5.

Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood.1985;66:1105-09.

Wandt H, Frank M, Ehninger G, Schneider C, Brack N, Daoud A, et al. Safety and cost effectiveness of a 10× 109/L trigger for prophylactic platelet transfusions compared with the traditional 20× 109/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91(10):3601-6.

Bayer WL, Bodensteiner DC, Tilzer LL, Adams ME. Use of platelets and other transfusion products in patients with malignancy. Semin Thromb Hemost. 1992;18(4):380-91.

Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol. 1997 Mar;15(3):1143-9.

Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med. 1997; 337(26): 1870-5.

Gauvin F, Lacroix J, Robillard P, Lapointe H, Hume H. Acute transfusion reactions in the pediatric intensive care unit. Transfusion. 2006 Nov 1;46(11):1899-908.

Slonim AD, Joseph JG, Turenne WM, Sharangpani A, Luban NL. Blood transfusions in children: a multi‐institutional analysis of practices and complications. Transfusion. 2008;48(1):73-80.

Tormey CA, Sweeney JD, Champion MH, Pisciotto PT, Snyder EL, Wu Y. Analysis of transfusion reactions associated with prestorage‐pooled platelet components. Transfusion. 2009;49(6):1242-7.

Janice P. Dutcher, Charles A. Schiffer, Joseph Aisner and Peter H. Wiernick. Long term follow-ups of patients with Leukemia Receiving Platelet Transfusions: Identification of a Large Group of Patients who denote become allo immunized. Blood 1981;58(5):1007-10.